Trial Profile
Pharmacokinetic Interaction and Safety/Tolerability Between NVP-1603-1 and NVP-1603-2 in Healthy Male Volunteers
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 08 Apr 2022
Price :
$35
*
At a glance
- Drugs NVP 1603 (Primary)
- Indications Pain
- Focus Pharmacokinetics
- Sponsors Navipharm
- 21 Aug 2019 Planned End Date changed from 31 Oct 2018 to 31 Jul 2020.
- 21 Aug 2019 Planned primary completion date changed from 28 Oct 2018 to 28 Mar 2020.
- 21 Aug 2019 Planned initiation date changed from 1 May 2018 to 1 Dec 2019.